0.6591
price up icon6.77%   0.0168
after-market 시간 외 거래: .65 -0.0091 -1.38%
loading
전일 마감가:
$0.6423
열려 있는:
$0.65
하루 거래량:
461.08K
Relative Volume:
0.09
시가총액:
$24.46M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
-0.2329
EPS:
-2.83
순현금흐름:
$-101.06M
1주 성능:
-3.92%
1개월 성능:
+50.03%
6개월 성능:
-73.00%
1년 성능:
-53.66%
1일 변동 폭
Value
$0.6204
$0.70
1주일 범위
Value
$0.6156
$0.7038
52주 변동 폭
Value
$0.4115
$4.2984

Athira Pharma Inc Stock (ATHA) Company Profile

Name
명칭
Athira Pharma Inc
Name
전화
(425) 620-8501
Name
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
직원
67
Name
트위터
Name
다음 수익 날짜
2024-12-07
Name
최신 SEC 제출 서류
Name
ATHA's Discussions on Twitter

ATHA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ATHA 0.6591 24.46M 0 -117.67M -101.06M -2.83
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-10-17 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 개시 Mizuho Buy
2022-06-23 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 다운그레이드 Jefferies Buy → Hold
2022-06-23 다운그레이드 Stifel Buy → Hold
2022-05-10 개시 BTIG Research Buy
2022-04-21 개시 Berenberg Buy
2021-12-15 개시 Goldman Neutral
2020-10-13 개시 Goldman Buy
2020-10-13 개시 JMP Securities Mkt Outperform
2020-10-13 개시 Jefferies Buy
2020-10-13 개시 Stifel Buy
모두보기

Athira Pharma Inc 주식(ATHA)의 최신 뉴스

pulisher
Nov 12, 2024

Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN

Nov 11, 2024
pulisher
Nov 08, 2024

Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive

Nov 08, 2024
pulisher
Nov 08, 2024

Athira Pharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times

Nov 07, 2024
pulisher
Nov 05, 2024

What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register

Nov 05, 2024
pulisher
Nov 04, 2024

Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360

Nov 04, 2024
pulisher
Nov 04, 2024

US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St

Nov 04, 2024
pulisher
Nov 01, 2024

Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com

Nov 01, 2024
pulisher
Oct 26, 2024

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN

Oct 26, 2024
pulisher
Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan

Oct 22, 2024
pulisher
Oct 18, 2024

Athira Pharma faces Nasdaq delisting over share price - Investing.com

Oct 18, 2024
pulisher
Oct 16, 2024

A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News

Oct 16, 2024
pulisher
Oct 07, 2024

A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex

Oct 07, 2024
pulisher
Sep 29, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 27, 2024
pulisher
Sep 26, 2024

Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily

Sep 26, 2024
pulisher
Sep 25, 2024

Check out these key findings about Athira Pharma Inc (ATHA) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Athira Pharma to lay off 70% of workforce - PharmaLive

Sep 23, 2024
pulisher
Sep 23, 2024

Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Athira Pharma to Lay Off 70% of Workforce - BioSpace

Sep 23, 2024
pulisher
Sep 20, 2024

After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech

Sep 20, 2024
pulisher
Sep 20, 2024

Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks

Sep 19, 2024
pulisher
Sep 18, 2024

Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Taking the lead: Athira Pharma Inc (ATHA) - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register

Sep 18, 2024
pulisher
Sep 18, 2024

Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter

Sep 18, 2024
pulisher
Sep 17, 2024

Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to Cut About 70% of Workforce - MarketWatch

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire

Sep 17, 2024
pulisher
Sep 17, 2024

Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire

Sep 17, 2024
pulisher
Sep 17, 2024

Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex

Sep 17, 2024
pulisher
Sep 16, 2024

Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily

Sep 16, 2024
pulisher
Sep 13, 2024

Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex

Sep 13, 2024
pulisher
Sep 12, 2024

AdPha urges HTA reform - Pharmacy Daily

Sep 12, 2024
pulisher
Sep 12, 2024

Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today

Sep 12, 2024

Athira Pharma Inc (ATHA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Athira Pharma Inc 주식 (ATHA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Gengos Andrew
CFO and Chief Business Officer
Sep 05 '24
Sale
0.57
1,272
720
97,532
Lenington Rachel
COO and CDO
Sep 05 '24
Sale
0.57
2,525
1,429
20,870
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Sep 05 '24
Sale
0.57
2,525
1,429
92,684
Worthington Mark
GENERAL COUNSEL
Sep 05 '24
Sale
0.57
2,525
1,429
51,927
Litton Mark James
President and CEO
Sep 05 '24
Sale
0.57
5,032
2,848
159,365
Romano Kelly A
Director
Jun 24 '24
Buy
2.42
27,400
66,179
80,715
Romano Kelly A
Director
Jun 21 '24
Buy
2.26
15,000
33,872
53,315
Litton Mark James
Chief Executive Officer
Jan 05 '24
Sale
2.91
4,820
14,026
144,397
Worthington Mark
General Counsel
Jan 05 '24
Sale
2.91
2,412
7,019
34,452
Lenington Rachel
Chief Operating Officer
Jan 05 '24
Sale
2.91
2,412
7,019
13,395
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
자본화:     |  볼륨(24시간):